Donor-derived anti-CD7 CAR T cells for relapsed or refractory T-ALL

Patients with relapsed or refractory T-cell acute lymphoblastic leukemia have few options and poor prognosis. A first-in-human phase 1 study in Beijing evaluated donor-derived anti-CD7 CAR T cells for R/R T-ALL. The CAR T cells exhibited efficient expansion and resulted in a high complete remission rate (90%) with a manageable safety profile.